Biotech's drug for Alzheimer's disease shows promise

07/30/2008 | Reuters

Rember, an Alzheimer's drug from biotechnology firm TauRX, significantly improved cognition and memory in patients with a moderate form of the disease, a Phase II study found. The experimental treatment works by dissolving tangles of the tau protein that are known to play a role in dementia. Other experts cautioned that it is too early to make conclusions from the study findings.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN